-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7

Benzinga·08/20/2026 10:01:59
Listen to the news
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.